On June 9, Life Biosciences announced that the first participant received a single intravitreal injection of ER-100, a gene therapy designed to reprogram the epigenetics of retinal ganglion cells back to a more youthful state. The patient has open-angle glaucoma, the leading cause of irreversible blindness in older adults. This is not a hypothesis or a target anymore, it is human data collection. No other company has yet dosed a human with a therapy that attempts to reverse aging at the epigenetic level.
The mechanism is simple enough to state and hard enough to execute: ER-100 delivers three genes, OCT4, SOX2, and KLF4 (referred to as OSK), via a modified adeno-associated virus (AAV) vector directly into the eye. These transcription factors reprogram cellular identity, resetting epigenetic marks that accumulate with age. In rodent models of retinal aging, OSK reverses functional decline in retinal ganglion cells, the neurons that die in glaucoma and never naturally regenerate. If the same biology holds in humans, ER-100 would be the first disease-modifying therapy for glaucoma that actually addresses cellular death rather than just lowering intraocular pressure, the symptom that existing drugs treat. Life Biosciences was co-founded by Harvard Medical School professor David Sinclair, whose lab generated the foundational preclinical work showing OSK could reverse epigenetic aging in retinal tissue. The FDA cleared the IND on January 15, 2026 (per Life Biosciences' pipeline page) or January 28, 2026 (per the public press release), approximately 4.5 months before the first patient dosing.
What makes glaucoma the chosen indication matters. The optic neuropathy space has roughly 3 million patients in the United States with open-angle glaucoma alone, yet no current therapy restores lost vision, all available treatments are pressure management. Retinal ganglion cell death is mechanically irreversible under existing biology. If an epigenetic reprogramming therapy can induce even modest regeneration or functional recovery in damaged RGCs, it clears a low bar for clinical differentiation. The Phase 1 trial will measure safety and tolerability first, but also assess visual function endpoints, a signal that the company and regulators already expect measurable improvement in vision, not just biomarkers of cellular activity. That expectation is aggressive. It means Life Biosciences is not running a traditional dose-escalation study to find a maximum tolerated dose; it is running a hypothesis-testing study in a population with high unmet need.
Life Biosciences operates with approximately 26 employees, funded by billionaire capital and venture backing, moving at a pace that would be impossible under traditional pharma timelines. The team compressed the path from preclinical validation to IND application to first-patient dosing in roughly two years, a cadence that reflects both the clarity of the mechanism and the capital density of the longevity market. This is not a Series B biotech with runway anxiety; this is a fully capitalized mission with a specific technical bet. What changes now is the question of durability and scale. The real test is not whether ER-100 is safe, it is whether partial epigenetic reprogramming in a immunologically protected tissue like the eye translates to systemic or CNS applications. If Phase 1 holds through 2026 and early 2027, expect Life Bio to file IND applications for additional indications within the retina and optic nerve. If visual function metrics improve, expect other programs targeting age-related neurodegeneration, Alzheimer's disease, Parkinson's disease, spinal cord injury, to accelerate. The first-patient dosing is not an endpoint; it is a permission structure for everything that comes next.